This “Spleen Tyrosine Kinase (SYK) Inhibitors- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Structure and Signaling of the SYK Receptor
SYK contains two tandem SH2 domains and a C-terminal tyrosine kinase domain. These domains are linked by two linker regions: interdomain A between the two SH2 domains and interdomain B between the C-terminal SH2 domain and the kinase domain. An alternatively spliced form of SYK (known as SYK-B) lacks 23 amino acids of interdomain B, including a nuclear localization signal.
The SYK signalling pathway was initially thought to be restricted to classical immunoreceptors of the adaptive immune response. However, later studies showing that glycoprotein VI (GpVI), a collagen-receptor expressed by platelets, also signals by a similar mechanism2, and that thepetechiated appearance of SYK-deficient embryos was due to a defect in lymphatic vascular development3 provided evidence for the role of SYK outside the adaptive immune response.
Expression
SYK is highly expressed by all haematopoietic lineage cells. Though the expression of SYK is tightly regulated the mechanism of this regulation, or that of the generation of the SYK-B isoform, is poorly understood. Mammals also express the SYK-related molecule ZAP70, the expression of which is mostly confined to the T and NK cell lineages.
Spleen Tyrosine Kinase (SYK) Inhibitors
While SYK inhibitors have shown positive effects in allergy, autoimmune diseases and B-lineage malignancies, the mechanism of their action is incompletely understood. This is in part due to the diverse roles of SYK in immunological functions. As an example, B-cell-mediated antigen presentation and autoantibody formation, Fc-receptor-mediated myeloid cell functions and ß2 integrin-mediated leukocyte activation have all been implicated in the pathogenesis of rheumatoid arthritis and they all have been shown to require SYK.
HMPL-523: Hutchison MediPharmaAn orally available inhibitor of spleen tyrosine kinase (Syk), with potential immune-modulating and antineoplastic activities. Upon oral administration of Syk inhibitor HMPL-523, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation.
This product will be delivered within 2 business days.
Geography Covered
- Global coverage
Spleen Tyrosine Kinase (SYK) Inhibitors Understanding
Spleen Tyrosine Kinase (SYK): Overview
SYK is a 72 kDa non-receptor tyrosine kinase, which contains two SRC homology 2 (SH2)-domains and a kinase domain, and is most highly expressed by haematopoietic cells. Mammals also express a SYK homologue, ZAP70, which is mostly restricted to T- and NK-lineage cells. SYK-related kinases are also found in invertebrates.Structure and Signaling of the SYK Receptor
SYK contains two tandem SH2 domains and a C-terminal tyrosine kinase domain. These domains are linked by two linker regions: interdomain A between the two SH2 domains and interdomain B between the C-terminal SH2 domain and the kinase domain. An alternatively spliced form of SYK (known as SYK-B) lacks 23 amino acids of interdomain B, including a nuclear localization signal.
The SYK signalling pathway was initially thought to be restricted to classical immunoreceptors of the adaptive immune response. However, later studies showing that glycoprotein VI (GpVI), a collagen-receptor expressed by platelets, also signals by a similar mechanism2, and that thepetechiated appearance of SYK-deficient embryos was due to a defect in lymphatic vascular development3 provided evidence for the role of SYK outside the adaptive immune response.
Expression
SYK is highly expressed by all haematopoietic lineage cells. Though the expression of SYK is tightly regulated the mechanism of this regulation, or that of the generation of the SYK-B isoform, is poorly understood. Mammals also express the SYK-related molecule ZAP70, the expression of which is mostly confined to the T and NK cell lineages.
Spleen Tyrosine Kinase (SYK) Inhibitors
While SYK inhibitors have shown positive effects in allergy, autoimmune diseases and B-lineage malignancies, the mechanism of their action is incompletely understood. This is in part due to the diverse roles of SYK in immunological functions. As an example, B-cell-mediated antigen presentation and autoantibody formation, Fc-receptor-mediated myeloid cell functions and ß2 integrin-mediated leukocyte activation have all been implicated in the pathogenesis of rheumatoid arthritis and they all have been shown to require SYK.
Spleen Tyrosine Kinase (SYK) Inhibitors Emerging Drugs Chapters
This segment of the Spleen Tyrosine Kinase (SYK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Spleen Tyrosine Kinase (SYK) Inhibitors Emerging Drugs
Cevidoplenib dimesylate: GenoscoThe dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage.HMPL-523: Hutchison MediPharmaAn orally available inhibitor of spleen tyrosine kinase (Syk), with potential immune-modulating and antineoplastic activities. Upon oral administration of Syk inhibitor HMPL-523, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation.
Spleen Tyrosine Kinase (SYK) Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Spleen Tyrosine Kinase (SYK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Spleen Tyrosine Kinase (SYK) Inhibitors
There are approx. 10+ key companies which are developing the therapies for Spleen Tyrosine Kinase (SYK) Inhibitors. The companies which have their Spleen Tyrosine Kinase (SYK) Inhibitors drug candidates in the most advanced stage, i.e. phase II and Phase II/III include, Rigel Pharmaceuticals, TopiVert etc.Phases
This report covers around 10+ products under different phases of clinical development like- Late-stage products (Phase II and Phase II/III)
- Mid-stage products (Phase II and Phase II/III)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Spleen Tyrosine Kinase (SYK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Oral
- Intravenous
Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal antibodies
- Small molecules
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Spleen Tyrosine Kinase (SYK) Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spleen Tyrosine Kinase (SYK) Inhibitors therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spleen Tyrosine Kinase (SYK) Inhibitors drugs.Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Spleen Tyrosine Kinase (SYK) Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Spleen Tyrosine Kinase (SYK) Inhibitors.
Spleen Tyrosine Kinase (SYK) Inhibitors Report Insights
- Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Spleen Tyrosine Kinase (SYK) Inhibitors Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:- How many companies are developing Spleen Tyrosine Kinase (SYK) Inhibitors drugs?
- How many Spleen Tyrosine Kinase (SYK) Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spleen Tyrosine Kinase (SYK) Inhibitors?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spleen Tyrosine Kinase (SYK) Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Spleen Tyrosine Kinase (SYK) Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Genosco
- Portola Pharmaceuticals
- GlaxoSmithKline
- FUJIFILM Corporation
- TopiVert
- Takeda Oncology
- Asana BioSciences
Key Products
- CVXL-0074
- Cevidoplenib
- PRT 2761
- GSK 2646264
- Cevidoplenib
- FF 10102 01
- TOP 1630
- Mivavotinib
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryDrug profiles in the detailed report…..Drug profiles in the detailed report…..Drug profiles in the detailed report…..Drug profiles in the detailed report…..Spleen tyrosine kinase inhibitors Key CompaniesSpleen tyrosine kinase inhibitors Key ProductsSpleen tyrosine kinase inhibitors- Unmet NeedsSpleen tyrosine kinase inhibitors- Market Drivers and BarriersSpleen tyrosine kinase inhibitors- Future Perspectives and ConclusionSpleen tyrosine kinase inhibitors Analyst ViewsSpleen tyrosine kinase inhibitors Key CompaniesAppendix
Spleen tyrosine kinase inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Fostamatinib: Rigel Pharmaceuticals
Mid Stage Products (Phase II)
Entospletinib: Kronos Bio
Early Stage Products (Phase I/II)
HM43239: Hanmi Pharmaceutical
Preclinical and Discovery Stage Products
Drug Name: Company Name
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Dermavant Sciences
- Rigel Pharmaceuticals
- Kronos Bio
- Hutchison MediPharma
- Hanmi Pharmaceutical
- Genosco
- Asana BioSciences
